Secondary Pharmacological Prevention of Coronary Artery Disease among Patients Submitted to Clinical Management, Percutaneous Coronary Intervention, or Coronary Artery Bypass Graft Surgery.
Marcelo B LuccaFelipe C FuchsAdriana S AlmeidaMarco V WainsteinFlavio D FuchsSandra Costa FuchsPublished in: Arquivos brasileiros de cardiologia (2023)
Patients with CAD submitted to CABG are more commonly treated with optimal pharmacological secondary prevention than patients treated by PCI or exclusively with medical therapy.
Keyphrases
- coronary artery bypass
- percutaneous coronary intervention
- coronary artery disease
- st segment elevation myocardial infarction
- coronary artery bypass grafting
- st elevation myocardial infarction
- acute myocardial infarction
- antiplatelet therapy
- acute coronary syndrome
- cardiovascular events
- heart failure
- stem cells
- newly diagnosed
- aortic valve
- cell therapy
- cardiovascular disease
- aortic stenosis
- minimally invasive
- surgical site infection